110 results on '"Sze, Daniel M."'
Search Results
2. PHYTOTHERAPEUTICS FOR CANCER THERAPY
3. Clonal expansions of cytotoxic T cells exist in the blood of patients with Waldenström macroglobulinemia but exhibit anergic properties and are eliminated by nucleoside analogue therapy
4. Either interleukin-12 or interferon-γ can correct the dendritic cell defect induced by transforming growth factor β1 in patients with myeloma
5. Extrafollicular antibody responses
6. Experimental models linking dendritic cell lineage, phenotype and function
7. Intrinsic Constraint on Plasmablast Growth and Extrinsic Limits of Plasma Cell Survival
8. T Helper 1 (Th1) and Th2 Characteristics Start to Develop During T Cell Priming and Are Associated with an Immediate Ability to Induce Immunoglobulin Class Switching
9. The changing preference of T and B cells for partners as T-dependent antibody responses develop
10. Dendritic cells from patients with myeloma are numerically normal but functionally defective as they fail to up-regulate CD80 (B7-1) expression after huCD40LT stimulation because of inhibition by transforming growth factor-β1 and interleukin-10
11. Clonal cytotoxic T cells are expanded in myeloma and reside in the CD8+CD57+CD28− compartment
12. What Are the Primary Limitations in B-Cell Affinity Maturation, and How Much Affinity Maturation Can We Drive with Vaccination?
13. Mining Symptom-Herb Patterns from Patient Records Using Tripartite Graph
14. An ethnopharmacological approach to the preliminary screening of native Australian herbal medicines for anticancer activity
15. Clonality Detection of Expanded T-Cell Populations in Patients With Multiple Myeloma
16. Immunomodulatory Activities ofGanoderma sinensePolysaccharides in Human Immune Cells
17. An Ensemble Approach for Record Matching in Data Linkage.
18. Potential Antioxidant, Antiinflammatory, and Proapoptotic Anticancer Activities of Kakadu Plum and Illawarra Plum Polyphenolic Fractions
19. Native Australian fruit polyphenols inhibit COX-2 and iNOS expression in LPS-activated murine macrophages
20. Antioxidant and cytoprotective activities of native Australian fruit polyphenols
21. Molecular Pathways for Cancer Chemoprevention by Dietary Phytochemicals
22. Abstract 2707: Investigation of the immunomodulatory effects of Radix Astragali targeting dendritic cells
23. Recirculating and germinal center B cells differentiate into cells responsive to polysaccharide-antigens
24. Extrafollicular antibody responses
25. Prognostically significant cytotoxic T cell clones are stimulated after thalidomide therapy in patients with multiple myeloma
26. Presence of Hoechst low side populations in multiple myeloma
27. Mining Symptom-Herb Patterns from Patient Records Using Tripartite Graph.
28. The Immunomodulatory Action of Thalidomide in Patients with Multiple Myeloma Involves a Clonal Expansion of Late-Differentiated Cytotoxic Effector Cells.
29. Development of Retargeted CD38-Specific NK-92 Cell Line for Potential Anti-Myeloma Immunotherapy.
30. Gene Expression Profiles of the Clinically Significant "Late" Stage Expanded Cytotoxic T Cells in Myeloma.
31. Either interleukin-12 or interferon-γ can correct the dendritic cell defect induced by transforming growth factor β 1 in patients with myeloma
32. Recirculating and germinal center B cells differentiate into cells responsive to polysaccharide antigens
33. Prediction of High Affinity Class I-restricted Multiple Myeloma Idiotype Peptide Epitopes
34. Clonal Cytotoxic T Cells in Myeloma
35. Experimental models linking dendritic cell lineage, phenotype and function
36. Low-level Hypermutation in T Cell–independent Germinal Centers Compared with High Mutation Rates Associated with T Cell–dependent Germinal Centers
37. Clonality Detection of Expanded T-Cell Populations in Patients With Multiple Myeloma.
38. T-independent type 2 antigens induce B cell proliferation in multiple splenic sites, but exponential growth is confined to extrafollicular foci
39. MicroRNAs Involved in Anti-Tumour Immunity.
40. Either interleukin-12 or interferon-γ can correct the dendritic cell defect induced by transforming growth factor β1 in patients with myeloma.
41. The Use of Thalidomide in Myeloma Therapy as an Effective Anticancer Drug
42. Dendritic cells from patients with myeloma are numerically normal but functionally defective as they fail to up-regulate CD80 (B7-1) expression after huCD40LT stimulation because of inhibition by transforming growth factor-β1and interleukin-10
43. T-independent type 2 antigens induce B cell proliferation in multiple splenic sites, but exponential growth is confined to extrafollicular foci
44. What Are the Primary Limitations in B-Cell Affinity Maturation, and How Much Affinity Maturation Can We Drive with Vaccination? A Role for Antibody Feedback.
45. Anthropometric profile of Hong Kong children and adolescents: the Wellness Population of Youth Study.
46. Immunomodulatory activities of Ganoderma sinense polysaccharides in human immune cells.
47. Native Australian fruit polyphenols inhibit cell viability and induce apoptosis in human cancer cell lines.
48. Towards the discovery of novel phytochemicals for disease prevention from native Australian plants: an ethnobotanical approach.
49. Development of Taxol and other endophyte produced anti-cancer agents.
50. Clonality detection of expanded T-cell populations in patients with multiple myeloma.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.